Home

Advancing scientific knowledge

Our Company

Driven by our dedication to improving outcomes in difficult-to-treat cancers, we are leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.

Read and download
our brochure

Our Science

Advancing antibody drug conjugates with a novel class of PBD dimers

Watch an MOA video about our first approved ADC, loncastuximab tesirine-lpyl (2:32)

Our Pipeline

A robust pipeline of investigational ADCs for the treatment of hematological cancers and solid tumors

Read and download the LOTIS brochure


Our Trials

Take a closer look at the LOTIS study designs


Recent Data

Explore the latest research from our scientists

A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression

HOPA, 2022

View Abstract
Mechanistic studies investigating the synergistic combination of Loncastuximab Tesirine and Ibrutinib in pre-clinical models of B-cell non-Hodgkin lymphoma

AACR, 2022

View Abstract
Effect of camidanlumab tesirine (Cami) as monotherapy and in combination with pembrolizumab (PEM) on the immune cell profile in patients with selected advanced solid tumors

AACR, 2022

View Abstract
HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)

NCCN, 2022

View Abstract
Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial

Alderuccio JP, Ai WZ, Radford, J, et al.

View Abstract
The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy

Caimi PF, Ardeshna KM, Reid E, et al.

View Abstract
Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma

Sachini N, Asma J, van Berkel PH, Zammarchi F.

View Abstract
CD19-Mediated DNA Damage Boost in Lymphoma Cells Treated with Loncastuximab Tesirine in Combination with PARP Inhibitors

Fusani S, Rossi A, Mazzara S, et al.

View Abstract
A Phase 1 Trial of Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory CD22+ B-Cell Acute Lymphoblastic Leukemia

Jain N, Jabbour EJ, Konopleva M, et al.

View Abstract
Budget Impact Model for Loncastuximab Tesirine-Lpyl in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Liao L, Yang C, Camardo J, et al.

View Abstract



MedConnect

Real-time answers to your pressing questions

Connect live with Medical Affairs

Our Company

Driven by our dedication to improving outcomes in difficult-to-treat cancers, we are leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.Read and download our brochure

Our Science

Advancing antibody drug conjugates with a novel class of PBD dimersADC Therapeutics’ proprietary ADCs are highly targeted drug constructs that combine monoclonal antibodies specific to surface tumor targets with a novel class of highly potent PBD-dimer toxins.PBD dimers do not distort the DNA structure, which makes them invisible to repair mechanisms and allows the cross-links to persist within the DNA. Unlike earlier generation PBD chemistry, ADC Therapeutics’ proprietary PBD dimers are not a substrate for multi-drug resistance proteins—even in hard-to-treat tumors.Our PBD-dimer technology: A novel approach to hematologic cancers and solid tumors

  • 1The antibody drug conjugate (ADC) binds to a specific tumor cell surface antigen and is internalized1,2
  • 2The potent pyrrolobenzodiazepine (PBD) dimer toxin is released inside the cell, where it then creates a covalent cross-link between the strands of the DNA double helix2,3
  • 3Because these cross-links do not distort the DNA structure, it is hypothesized that they remain invisible to repair mechanisms and can covertly persist to interrupt cell division and cause tumor cell death1-3

Watch an MOA video about our first approved ADC, loncastuximab tesirine-lpyl (2:32)

Our Pipeline

A robust pipeline of investigational ADCs for the treatment of hematological cancers and solid tumorsADCT has multiple PBD-based ADCs in ongoing clinical trials and numerous preclinical ADCs in development.Some of the agents represented in this pipeline chart are investigational. Efficacy and safety have not yet been established.

* LOTIS-6 trial currently on hold

Expand each compound to learn more.

LONCASTUXIMAB TESIRINE-lpyl

Loncastuximab tesirine-lpyl is an ADC composed of a humanized monoclonal antibody that binds to human CD19 and is conjugated through a linker to a PBD–dimer toxin. CD19 is a clinically validated target for the treatment of B-cell malignancies.

Hematology Franchise Clinical Trials

CAMIDANLUMAB TESIRINE

Camidanlumab tesirine, ADCT’s second lead candidate, has demonstrated significant clinical activity in heavily pretreated patients with Hodgkin lymphoma. Based on its mechanism targeting CD25/regulatory T cells, camidanlumab tesirine is also demonstrating potential in the treatment of solid tumors.

Hematology Franchise Clinical Trial

Solid Tumor Franchise Clinical Trial

adct-602

ADCT-602 is an ADC composed of a monoclonal antibody that binds to CD22 conjugated to a PBD-dimer toxin. CD22 is highly expressed on most malignant B-cells, including expression in more than 90% of patients with B-cell acute lymphoblastic leukemia (ALL). ADCT-602 is being evaluated in a phase I/II clinical trial in patients with relapsed or refractory B-cell ALL.

Hematology Franchise Clinical Trial

adct-601

ADCT-601 is an ADC composed of a humanized monoclonal antibody that binds to human AXL (licensed from BerGenBio), conjugated using Glycoconnect™ technology (licensed from Synaffix BV) to a linker with a PBD-dimer toxin. AXL is highly overexpressed in many solid tumors and hematological malignancies. ADCT-601 is being evaluated in a phase 1 clinical trial in patients with selected advanced solid tumors.
adct-901

ADCT-901 is an ADC composed of a humanized monoclonal antibody (3A4) directed against human KAAG1 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD–dimer cytotoxin. KAAG1 has high expression in tumors with high unmet medical need, while its expression on healthy tissue is very restricted. ADCT-901 is being developed for the treatment of advanced solid tumors with high unmet medical needs, including platinum resistant ovarian cancer and triple negative breast cancer.

Solid Tumor Franchise Clinical Trial

adct-701

ADCT-701 is an ADC composed of a humanized monoclonal antibody (HuBa-1-3D) directed against human DLK-1 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD-dimer cytotoxin. DLK-1 is an attractive novel tumor target for ADC development as it is expressed in adults in several tumors. ADCT-701 is being developed for the treatment of advanced solid tumors with high unmet medical needs, neuroblastoma, hepatocellular carcinoma, and small cell lung cancer.

Learn more about our pipeline
Read and download the LOTIS brochure

Our Trials

Take a closer look at the LOTIS study designs

Recent Data

Explore the latest research from our scientists

A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of MyelosuppressionHOPA, 2022View Abstract
Mechanistic studies investigating the synergistic combination of Loncastuximab Tesirine and Ibrutinib in pre-clinical models of B-cell non-Hodgkin lymphomaAACR, 2022View Abstract
Effect of camidanlumab tesirine (Cami) as monotherapy and in combination with pembrolizumab (PEM) on the immune cell profile in patients with selected advanced solid tumorsAACR, 2022View Abstract
HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)NCCN, 2022View Abstract
Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical TrialAlderuccio JP, Ai WZ, Radford, J, et al.View Abstract
The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell TherapyCaimi PF, Ardeshna KM, Reid E, et al.View Abstract
Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin LymphomaSachini N, Asma J, van Berkel PH, Zammarchi F.View Abstract
CD19-Mediated DNA Damage Boost in Lymphoma Cells Treated with Loncastuximab Tesirine in Combination with PARP InhibitorsFusani S, Rossi A, Mazzara S, et al.View Abstract
A Phase 1 Trial of Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory CD22+ B-Cell Acute Lymphoblastic LeukemiaJain N, Jabbour EJ, Konopleva M, et al.View Abstract
Budget Impact Model for Loncastuximab Tesirine-Lpyl in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaLiao L, Yang C, Camardo J, et al.View Abstract